SQUMJ-Sultan Qaboos University Medical Journal. 2010; 10 (3): 312-317
em Inglês
| IMEMR
| ID: emr-143775
ABSTRACT
Infection with the hepatitis C virus [HCV] is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic.Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid [MicroRNA] that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
RNA
/
Interferons
/
Hepacivirus
/
Hepatite C Crônica
Limite:
Humanos
Idioma:
Inglês
Revista:
Sultan Qaboos Univ. Med. J.
Ano de publicação:
2010
Similares
MEDLINE
...
LILACS
LIS